Recruitment period

• Open until full

Location of study/trial

• Virginia Mason MS Center, Seattle, WA

Recruiting

• The main purpose of this study is to compare 2 doses of fingolimod (0.25 mg and 0.5 mg) with glatiramer acetate 20 mg and to evaluate the effectiveness and safety of fingolimod 0.25 mg for people with RRMS.
• Male and female patients 18 to 65 years of age, inclusive
• Patients with RRMS, as defined by 2010 revised McDonald criteria
• Patients must be neurologically stable with no onset of relapse or any steroid use within 30 days of randomization
• Patients with at least 1 documented relapse during the previous year or 2 documented relapses during the previous 2 years before randomization
• Patients with an EDSS score of 0 to 6 inclusive at Screening. A score of 6.0 indicates unilateral assistance (cane or crutch) required to walk at least 100 meters with or without resting
   

Principal investigator

• Mariko Kita, MD